{
  "timestamp": "2025-12-26T10:53:08.398804",
  "validator": "validate_ov_nf1_playbook",
  "fixture": "/Users/fahadkiani/Desktop/development/crispr-assistant-main/oncology-coPilot/oncology-backend-minimal/data/patient_states/OV-NF1-001.json",
  "overall_passed": true,
  "checks": [
    {
      "name": "nf1_playbook_static",
      "passed": true,
      "details": "NF1 playbook entry present with expected RR/source/alternatives",
      "metrics": {
        "relative_risk": 2.1,
        "validation_source": "TCGA_OV_469",
        "alt_drugs": [
          "bevacizumab",
          "olaparib",
          "trametinib"
        ]
      }
    },
    {
      "name": "nf1_playbook_service",
      "passed": true,
      "details": "Playbook service returns expected NF1 alternatives + provenance",
      "metrics": {
        "alternatives_count": 3,
        "alt_drugs": [
          "bevacizumab",
          "olaparib",
          "trametinib"
        ],
        "regimen_changes_count": 1,
        "monitoring_changes": {
          "mrd_frequency": null,
          "ctdna_targets": null,
          "imaging_frequency": "CT every 2-3 months",
          "biomarker_frequency": "CA-125 every 2 weeks",
          "bone_marrow_frequency": null
        },
        "provenance": {
          "service_version": "resistance_playbook_v1.0_dry",
          "disease": "ovarian",
          "detected_resistance": [
            "NF1"
          ],
          "cytogenetics": null,
          "treatment_line": 1,
          "prior_therapies": [],
          "line_multiplier_applied": 1.0,
          "cross_resistance_detected": [],
          "playbook_source": "OV_RESISTANCE_PLAYBOOK",
          "alternatives_count": 3,
          "regimen_changes_count": 1
        }
      }
    },
    {
      "name": "nf1_regimen_monitoring",
      "passed": true,
      "details": "NF1 includes regimen change + intensified monitoring guidance",
      "metrics": {
        "regimen_changes": [
          {
            "from_regimen": "carboplatin/paclitaxel",
            "to_regimen": "carboplatin/paclitaxel + bevacizumab",
            "rationale": "Add bevacizumab for high-risk disease",
            "evidence_level": "VALIDATED"
          }
        ],
        "biomarker_frequency": "CA-125 every 2 weeks",
        "imaging_frequency": "CT every 2-3 months"
      }
    }
  ]
}